Brokers Set Expectations for Immunic FY2025 Earnings

Immunic, Inc. (NASDAQ:IMUX) – Research analysts at William Blair issued their FY2025 earnings estimates for shares of Immunic in a note issued to investors on Monday, March 24th. William Blair analyst M. Minter expects that the company will post earnings per share of ($0.89) for the year. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Immunic’s current full-year earnings is ($0.94) per share.

Several other research firms have also commented on IMUX. D. Boral Capital reaffirmed a “buy” rating and set a $17.00 price objective on shares of Immunic in a research note on Wednesday, February 26th. HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Immunic in a report on Friday, February 21st. Finally, StockNews.com downgraded shares of Immunic from a “hold” rating to a “sell” rating in a research note on Thursday, March 20th. One investment analyst has rated the stock with a sell rating, seven have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $12.67.

Immunic Stock Performance

Shares of Immunic stock opened at $1.25 on Wednesday. The stock has a market cap of $112.60 million, a price-to-earnings ratio of -1.02 and a beta of 1.89. The stock has a 50 day moving average price of $1.07 and a 200-day moving average price of $1.21. Immunic has a one year low of $0.92 and a one year high of $2.11.

Hedge Funds Weigh In On Immunic

Institutional investors have recently modified their holdings of the stock. Invesco Ltd. bought a new position in Immunic in the fourth quarter worth approximately $37,000. Virtu Financial LLC purchased a new stake in shares of Immunic in the 3rd quarter worth $50,000. HB Wealth Management LLC bought a new position in shares of Immunic during the 4th quarter worth $81,000. Barclays PLC purchased a new position in shares of Immunic during the fourth quarter valued at $84,000. Finally, Jane Street Group LLC raised its holdings in shares of Immunic by 121.4% in the third quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock valued at $116,000 after acquiring an additional 38,553 shares in the last quarter. 51.82% of the stock is owned by hedge funds and other institutional investors.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.